New research from the Spastic Paraplegia Centers of Excellence Research Network (SP-CERN). This summary is based on a paper published in the journal Annals of Clinical and Translational Neurology on April 25, 2026, titled "Movement Disorders in Aicardi–Goutières Syndrome and Response to Immunomodulation." 

Read the paper here. 

Learn more about SP-CERN. 

Transcript: 

New research from the Spastic Paraplegia Centers of Excellence Research Network (SP-CERN), a research group of the Rare Diseases Clinical Research Network.

Characterizing Movement Disorders and Treatment Responses in Aicardi-Goutières Syndrome.

This summary is based on a paper published in the journal Annals of Clinical and Translational Neurology on April 25, 2026.

Aicardi-Goutières syndrome (AGS) is a genetic autoinflammatory disorder primarily affecting the brain, skin, and immune system. Individuals with AGS can experience a wide range of neurological symptoms, even when they have the same gene mutation, causing many to be misdiagnosed as having cerebral palsy.

In this study, researchers characterized movement disorders and treatment responses in AGS. The team evaluated motor symptoms, neuroimaging, and interferon signatures in seven children with AGS treated with immunomodulatory therapies.

Results show that these therapies were associated with reduced systemic inflammation and stabilized disease. However, only some participants experienced improved motor function, suggesting that established central nervous system injury may limit recovery. Authors note that these findings highlight the need for early recognition and treatment before further injury may occur.